6 курс / Кардиология / СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ

Литература

в зависимости от пола и возраста // Российский кардиологический журнал. – 2005. – № 3. – С. 63–68.

111.Шевченко А.В., Голованова О.В., Коненков В.И. и др. Анализ взаимосвязи полиморфизма гена IL6 (;174 G/C) и классических факторов риска у пациентов с острым инфарктом миокарда в анамнезе // Медицинская иммунология. – 2009. – № 6. – С. 557–566.

112.Шилов С.Н. Хроническая сердечная недостаточность при ишемической болезни сердца: клинико;генетические механизмы развития и возможности улучшения ранней диагностики, профилактики и медикаментозной терапии : автореф. дис. … докт. мед. наук. – Томск, 2011. – 50 с.

113.Шляхто Е.В., Конради А.О. Роль генетических факторов в ремоделировании сердечно;сосудистой системы при гипертонической болезни // Артериальная гипертензия. – 2002 – Т. 4, № 3. – С. 22–29.

114.Шляхто Е.В., Конради А.О., Моисеева О.М. Молекулярно; генетические и клеточные аспекты ремоделирования сердца

исосудов при гипертонической болезни (обзор) // Терапевтический архив. – 2004. – № 6. – С. 51–58.

115.Шувалова Ю.А., Каминный А.И., Мешков А.Н. и др. Полиморфизм Prol98Leu гена GPХ;1 и активность эритроцитарной глутатионпероксидазы и продуктов перекисного окисления липидов // Бюллетень экспериментальной биологии и медицины. – 2010. – № 6. – С. 682–685.

116.Щербакова М.Ю., Старцева А.И. Профилактика сердечно; сосудистой патологии у детей группы высокого риска // Лечащий врач. – 2003. – № 2. – С. 36–38.

117.Яковлева А.С., Миролюбова О.А., Холматова К.К. и др. Влияние воспалительно;метаболического статуса больных

иметодов миокардиальной реперфузии на сывороточные уровни биомаркера апоптоза растворимого FAS;лиганда в раннем постинфарктном периоде // Цитокины и воспаление.

– 2012. – № 1. – С. 73–79.

359

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

118.Ярилин А.А. Апоптоз. Природа феномена. Его роль в целостном организме // Патофизиология и экспериментальная терапия. – 1998. – № 2. – С. 43–48.

119.Abbate A., Biondi;Zoccai G.G.L., Bussani R. et al. Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post;infarction heart failure // J. Am. Coll. Cardiol. – 2003. – Vol. 41. – P. 753–760.

120.Abilleira S., Bevan S., Markus H.S. The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclero; sis // J. Med. Genet. – 2006. – Vol. 43 (12). – Р. 897–901.

121.Adam;Klages S., Adam D., Weigmann K. et al. FAN, a novel WD; repeat protein, couples the p55 TNF;receptor to neutral sphin gomyelinase // Cell. – 1996. – Vol. 86. – P. 937–947.

122.Adler V., Yin Z., Fuchs S.Y. et al. Regulation of JNK signaling by GSTp // EMBO J. – 1999. – Vol. 18. – Р. 1321–1334.

123.Agnoletti L., Curello S., Bachetti T. et al. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor;alpha // Circulation. – 1999. – Vol. 100. – P. 1983–1991.

124.Agoston;Coldea L., Mocan T., Gatfosse M. et al. Plasma ho; mocysteine and the severity of heart failure in patients with pre; vious myocardial infarction // Cardiol. J. – 2011. – Vol. 18. – Р. 55–62.

125.Aharinejad S., Andrukhova O., Lucas T. et al. Programmed cell death in idiopathic dilated cardiomyopathy is mediated by sup; pression of the apoptosis inhibitor apolion // Ann. Thorac. Surg.

– 2008. – Vol. 86. – P. 109–114.

126.Ahmet I., Tae H.J., Juhaszova M. et al. A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage // Mol. Med. – 2010. – Vol. 16. – Р. 167–168.

127.Albina J.E., Cui S., Mateo R.B. et al. Nitric Oxidi – Medeated Ap; optosis in Murine Peretoneal Macrophages // J. Immunol. – 1993.

– Vol. 150 (II). – Р. 5080–5085.

360

Литература

128.Alioglu E., Turk U., Cam S. et al Polymorphisms of the methyle; netetrahydrofolate reductase, vascular endothelial growth fac; tor, endothelial nitric oxide synthase, monocyte chemoattracta; nt protein;1 and apolipoprotein E genes are not associated with carotid intima;media thickness // Can. J. Cardiol. – 2009. – Vol. 25 (1). – Р. 1–5.

129.Ali;Osman F., Akande O., Antoun G. et al. Molecular cloning, char; acterization, and expression in Escherichia coli of full;length cDNAs of three human glutathione S;transferase Pi gene vari; ants: evidence for differential catalytic activity of the encoded proteins // J. Biol. Chem. – 1997. – Vol. 272. – Р. 10004–10012.

130.Andersen P.M., Sims K.B., Xin W.W. et al. Sixteen novel muta; tions in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes // Amyotroph. Lateral Scler. Other Motor. Neuron. Disord. – 2003.

– Vol. 4. – Р. 62–73.

131.Andrae J., Gallini R., Betsholtz C. Role of platelet;derived growth factors in physiology and medicine // Genes Dev. – 2008. – Vol. 22. – Р. 1276–1312.

132.Angelini A., Maiolino G., La Canna C. et al. Relevance of apopto; sis in influencing recovery of hibernating myocardium // Eur. J. Heart Fail. – 2007. – Vol. 9 (4). – P. 377–383.

133.Anker S.D., Haehling S. Inflammatory mediators in chronic heart failure: an overview // Heart. – 2004. – Vol. 90. – P. 464–470.

134.Ara S., Lee P.S.Y., Hansen M.F. et al. Codon 72 polymorphism of the TP53 gene // Nucleic Acids Research. – 1990. – Vol. 18, No. 16. – P. 4961.

135.Araki S., Shimada Y., Kaji K. et al. Apoptosis of vascular endothe; lial cells by fibroblast growth factor deprivation // Biochem. Bio; phys. Res. Commun. – 1990. – Vol. 168. – Р. 1194–1200.

136.Arden K.C., Viars C.S., Weiss S. et al. Localization of the human B;type natriuretic peptide precursor (NPPB) gene to chromo; some 1p36 // Genomics. – 1995. – Vol. 26 (2). – Р. 385–389.

137.Ardissino D., Mannucci P.M., Merlini P.A. et al. Prothrombotic

361

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

genetic risk factors in young survivors of myocardial infarction // Blood. – 1999. – Vol. 94 (1). – Р. 46–51.

138.Arima Y., Nitta M., Kuninaka S. et al. Transcriptional Blockade Induces p53;dependent Apoptosis Associated with Transloca; tion of p53 to Mitochondria // Biol. Chem. – 2005. – Vol. 280 (19). – Р. 19166–19176.

139.Artuc M., Karman D., Jurgovsky K. et al. Analysis of human mel; anoma cell sublines displaying various levels of drug resistance against Cisplatin, Fotemustine, Vindesine or Etoposide // Anti; cancer. – 1997. – Vol. 17. – P. 4359–4370.

140.Atasoy Р., Bozdogan O., Erekul S. et al. Fas;mediated pathway and apoptosis in normal, hyperplastic, and neoplastic endometri; um // Gynecologic Oncology. – 2003. – Vol. 91 (2). – Р. 309– 317.

141.Awata T., Inoue K., Kurihara S. et al. A common polymorphism in the 5;untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes // Diabetes. – 2002. – Vol. 51 (5). – P. 1635–1639.

142.Azevedo L.C., Pedro M.A., Souza L.C. Oxidative stress as a sig; naling mechanism of the vascular response to injury: the redox hypothesis of restenosis // Cardiovasc. Res. – 2000. – Vol. 47

(3). – Р. 436–445.

143.Azzazy H.M., Christenson R.H. B;type natriuretic peptide: phys; iologic role and assay characteristics // Heart Fail. Rev. – 2003.

– Vol. 8. – Р. 315–320.

144.Baker A.H., Zaltsman A.B., George S.J. Divergent effects of tis; sue inhibitor of metalloproteinase;1, ;2 or ;3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP; 3 promotes apoptosis // J. Clin. Invest. – 1998. – Vol. 101. – P. 1478–1487.

145.Baldi A., Abbate A., Bussani R. et al. Apoptosis and post;infarc; tion left ventricular remodeling // J. Mol. Cell Cardiol. – 2002. – Vol. 34. – P. 165–174.

146.Balsam L.B., Kofidis T., Robbins R.C. Caspase;3 inhibition pre;

362

Литература

serves myocardial geometry and long;term function after infarc; tion // J. Surg. Res. – 2005. – Vol. 124. – P. 194–200.

147.Bay M., Kirk V., Parner J. et al. NT;proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function // Heart. – 2003. – Vol. 89. – Р. 150–154.

148.Beckman G., Birgander R., Sjalander A., et al. Is p53 polymor; phism maintained by natural selection? // Hum. Hered. – 1994.

–Vol. 44. – P. 266–270.

149.Beckman J.S., Koppenol W.H. Nitric oxide, superoxide and per; oxinitrite: the gool, the bad and ugly // Am. J. Physiol. – 1996. – Vol. 5. – Р. 1424–1437.

150.Benjamin I.J. Matrix metalloproteinases: from biology to thera; peutic strategies in cardiovascular disease // J. Invest. Med. – 2001. – Vol. 49. – P. 381–397.

151.Bettencourt P., Azevedo A., Pimenta J. et al. N;terminal pro;brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients // Circulation. – 2004. – Vol. 110. – Р. 2168– 2174.

152.Bing O.H. Hypothesis: apoptosis may be a mechanism for the transition to heart failure with chronic pressure overload // J. Mol. Cell. Cardiol. – 1994. – Vol. 26 (8). – Р. 943–948.

153.Blanco R.R., Austin H., Vest R.N. et al. Angiotensin receptor type 1 single nucleotide polymorphism 1166A/C is associated with malignant arrhythmias and altered circulating miR;155 levels in patients with chronic heart failure // J. Card. Fail. – 2012. – Vol. 18 (9). – P. 717–723.

154.Blann A.D., Belgore F.M., McCollum C.N. et al. Vascular endot; helial growth factor and its receptor, FLT;1, in the plasma of pa; tients with coronary or peripheral atherosclerosis, or type II dia; betes // Clin. Sci. – 2002. – Vol. 102. – P. 187–194.

155.Bleumink G.S., Schut A.F., Sturkenboom M.C. et al. Genetic poly; morphisms and heart failure // Genet. Med. – 2004. – Vol. 6 (6).

–P. 465–474.

363

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

156.Boffa G.M., Zaninotto M., Bacchiega E. et al. Correlations be; tween clinical presentation, brain natriuretic peptide, big endot; helin;1, tumor necrosis factor;alpha and cardiac troponins in heart failure patients // Ital. Heart J. – 2005. – Vol. 6. – P. 125– 132.

157.Bohm F., Beltran E., Pernow J. Endothelin receptor blockade im; proves endothelial function in atherosclerotic patients on angio; tensin converting enzyme inhibition // J. Intern. Med. – 2005. – Vol. 257. – P. 263–271.

158.Bonafe M., Salvioli S., Barbi C. et al. The different apoptotic po; tential of the p53 codon 72 alleles increases with age and modu; lates in vivo ischaemia;induced cell death // Cell Death Differ. – 2004. – Vol. 11. – P. 962–973.

159.Bonner J.C. Regulation of PDGF and its receptors in fibrotic dis; eases // Cytokine Growth Factor Rev. – 2004. – Vol. 15 (4). – Р. 255–273.

160.Booz G.W., Baker K.M. Molecular signalling mechanisms con; trolling growth and function of cardiac fibroblasts // Cardiovasc. Res. – 1995. – Vol. 30 (4). – P. 537–543.

161.Bots M.L., Witteman J.C., Hoffman A. et al. Low diastolic blood pressure and atherosclerosis in elderly subjects. The Rotterdam study // Arch. Intern. Med. – 1996. – Vol. 156. – Р. 843–848.

162.Bott;Flugel L., Weig H.J., Uhlein H. et al. Quantitative analysis of apoptotic markers in human end;stage heart failure // Eur. J. Heart Fail. – 2008. – Vol. 10 (2). – Р. 129–132.

163.Boushey C.J., Beresford S.A.A., Omenn G.S. et al. A quantitive assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increas-ing folic acid intakes // JAMA. – 1995. – Vol. 274. – P. 1049–1057.

164.Braunwald E., Bristow M.R. Congestive heart failure: fifty years of progress // Circulation. – 2000. – Vol. 102. – Р. 14–23.

165.Bray P.F. Integrin polymorphisms as risk factors for thrombosis // Thromb. Haemost. – 1999. – Vol. 82. – P. 337–344.

166.Bristow M.R. Tumor necrosis factor and cardimyopathy // Circu;

364

Литература

lation. – 1999. – Vol. 97. – Р. 1340–1342.

167.Brugada R., Kelsey W., Lechin M. et al. Role of candidate modi; fier genes on the phenotypic expression of hypertrophy in pa; tients with hypertrophic cardiomyopathy // J. Investig Ned. – 1997. – Vol. 45. – Р. 542–551.

168.Bruno B.G., Piazza L.A., de Bold A.J. BNP gene expression is specifically modulated by stretch and ET;1 in a new model of iso; lated rat atria // Am. J. Physiol. – 1997. – Vol. 273. – Р. 2678– 2686.

169.Burn S., Walters M., Caplin J. The hibernating heart: reversible left ventricular dysfunction in chronic heart failure // Postgradu; ate Med. J. – 1999. – Vol. 75 (885). – P. 419–421.

170.Burstein B., Libby E., Calderone A. et al. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet; derived growth factor in atrial;ventricular remodeling differenc; es // Circulation. – 2008. – Vol. 117 (13). – Р. 1630–1641.

171.Cai W., Devaux B., Schaper W. et al. The role of Fas/APO 1 and apoptosis in the development of human at herosclerotic lesions // Atherosclerosis. – 1997. – Vol. 131. – P. 177–186.

172.Carmeliet P. Angiogenesis in life, disease and medicine // Na; ture. – 2005. – Vol. 438. – Р. 932–936.

173.Carmeliet P., Ng Y.;S., Nuyens D. et al. Impaired myocardial an; giogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188 // Nat. Med. – 1999. – Vol. 5. – Р. 495–502.

174.Carter A.M., Catto A.J., Bamford J.M. et al. Platelet GP IIIa PlA and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke // Arterioscler. Thromb. Vasc. Biol. – 1998. – Vol. 18, No. 7. – P. 1124–1131.

175.Castejon A.M., Bracero J., Hoffmann I.S. et al. NAD(P)H oxidase p22phox gene C242T polymorphism, nitric oxide production, salt sensitivity and cardiovascular risk factors in Hispanics // J. Hum. Hypertens. – 2006. – Vol. 20, No. 10. – Р. 772–779.

176.Catuzzo B., Ciancamerla F., Bobbio M. et al. In patients with se;

365

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

vere systolic dysfunction, only brain natriuretic peptide is related to diastolic restrictive pattern // J. Card. Fail. – 2003. – Vol. 9. –

Р.303–310.

177.Ceconi C., Curello S., Bachetti T. et al. Tumor necrosis factor in congestive heart failure: a mechanism of disease for the new millennium // Prog. Cardiovasc. Dis. – 1998. – Vol. 41 (1). –

Р.25–30.

178.Chatterjee S., Stewart A.S., Bish L.T. et al. Viral gene transfer of the antiapoptotic factor Bcl;2 protects against chronic postis; chemic heart failure // Circulation. – 2002. – Vol. 106. – P. I212– I217.

179.Chin B.S., Blann A.D., Gibbs C.R. et al. Prognostic value of inter; leukin;6, plasma viscosity, fibrinogen, von Willebrand factor, tis; sue factor and vascular endothelial growth factor levels in con; gestive heart failure // Eur. J. Clin. Invest. – 2003. – Vol. 33 (11).

– Р. 941–948.

180.Chiu C., Ingles J., Lind J.M., Semsarian C. Mutation analysis of the natriuretic peptide precursor B (NPPB) gene in patients with hypertrophic cardiomyopathy // DNA Seq. – 2006. – Vol. 17 (5).

– Р. 392–395.

181.Chiurchiu V., Izzi V., D’Aquilio F. et al. Brain Natriuretic Peptide (BNP) regulates the production of inflammatory mediators in human THP;1 macrophages // Regul. Pept. – 2008. – Vol. 148 (1–3). – Р. 26–32.

182.Christian F., Ansel P., Behzad O. FGF23 induces left ventricular hypertrophy // J. Clin. Invest. – 2011. – Vol. 121 (11). – Р. 4393– 4408.

183.Cleland J.G., Swedberg K., Follath F. et al. The EuroHeart Failure Survey Programme – a survey on the quality of care among pa; tients with heart failure in Europe // Eur. Heart J. – 2003. – Vol. 24.

– Р. 442–475.

184.Clerico A., Edmin M. Diagnostic accuracy and prognostic rele; vance of the measurement of cardiac natriuretic peptides: a re; view // Clin. Chem. – 2004. – Vol. 6. – Р. 33–50.

366

Литература

185.Cohen G.M. Caspases: the executioners of apoptosis // Biochem. J. – 1997. – Vol. 326. – Р. 1–16.

186.Cohn J.N., Tognoni G. A randomized trial of the angiotensin;re; ceptor blocker valsartan in chronic heart failure // N. Engl. J. Med.

– 2001. – Vol. 345. – P. 1667–1675.

187.Collinson D., Donnelly R. Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collat; eral circulation? // Eur. J. Vasc. Endovasc. Surg. – 2004. – Vol. 28. – Р. 9–23.

188.Colucci W.S. Apoptosis in the heart // N. Engl. J. Med. – 1996. – Vol. 335. – Р. 1224–1226.

189.Condell R.A., Tappel A.L. Evidence for suitability of glutathione peroxidase protective enzyme: studies of oxidative damage, and proteolysis // Arch. Biochem. Biophys. – 1983. – Vol. 223 (2). – Р. 407–416.

190.Conway E.M., Collen D., Carmeliet P. Molecular mechanisms of blood vessel growth // Cardiovasc Res. – 2001. – Vol. 49 (3). – Р. 507–521.

191.Cook S.A., Poole;Wilson P.A. Cardiac myocyte apoptosis // Eur. Heart J. – 1999 – Vol. 20 (22). – Р. 1619–1629.

192.Creemers E., Cleutjens J., Smits J. Matrix metallopro-teinase inhibition after myocardial infarction: a new approach to prevent heart failure? // Circ. Res. – 2001. – Vol. 89. – P. 201–210.

193.Crow M.T., Mani K., Nam Y.J. et al. The mitochondrial death path; way and cardiac myocyte apoptosis // Circ. Res. – 2004. – Vol. 95 (10). – Р. 957;970.

194.D’Agostini F., Fronza G., Campomenosi P. et al. Cancer biomark; ers in human atherosclerotic lesions: no evidence of p53 involve; ment // Cancer Epidemiol. Biomarkers Prev. – 1995. – Vol. 4 (2).

– Р. 111–115.

195.Dalal M., Sun K., Cappola A.R. et al. Relationship of serum fibro; blast growth factor 23 with cardiovascular disease in older com; munity;dwelling women // Eur. J. Endocrinol. – 2011. – Vol. 165

(5). – Р. 797–803.

367

Тепляков А.Т., Березикова Е.Н., Шилов С.Н. Сердечная недостаточность

196.Dandona P., Ghanim H., Brooks D. Antioxidant activity of carvedilol in cardiovascular disease // J. Hypertens. – 2007. – Vol. 25 (4).

–Р. 731–741.

197.Das A., Xi L., Kukreja R.C. Phosphodiesterase;5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apo; ptosis // J. Biol. Chem. – 2005. – Vol. 280 (13). – Р. 12944–12955.

198.Davignon J., Ganz P. Role of endothelial dysfunction in athero; sclerosis // Circulation. – 2004. – Vol. 109. – Р. 27–32.

199.De Bruyne M.C., Hoes A.W., Kors J.A. et al. QTc dispersion pre; dicts cardiac mortality in the alderly: the Rotterdam study // Cir; culation. – 1998. – Vol. 97. – Р. 467–472.

200.De Filippi C.R., Christenon R.H., Gottdiener J.S. et al. Dynamic cardiovascular risk assessment in elderly people: the role of re; peated N;terminal pro;B;type natriuretic peptide testing // J. Am. Coll. Cardiol. – 2010. – Vol. 55 (5). – Р. 441–450.

201.De Lemos J.A., McGuire D.K., Drazner M.H. B;type natriuretic peptide in cardiovascular disease // Lancet. – 2003. – Vol. 362.

–Р. 316–323.

202.Del Ry S., Morales M.A., Scali M.C. et al. Effect of concomitant oral chronic dipyridamole therapy on inflammatory cytokines in heart failure patients // Clin. Lab. – 2013. – Vol. 59 (7–8). – P. 843–849.

203.Denus S., Pharand C., Williamson D. Brain natriuretic peptide in the management of heart failure // Chest. – 2004. – Vol. 125. – Р. 652–668.

204.Dhalla N.S., Temsah R.M., Netticadan T. Role of oxidative stress in cardiovascular diseases // J. Hypertens. – 2000. – Vol. 18 (6).

–P. 655–673.

205.Dinarello C.A. Interleukin;1 // Cytokine and Growth Factor Re; views. – 1997. – Vol. 8 (4). – P. 253–265.

206.Diwan A., Dorn G.W. Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets // Physiolo; gy. – 2007. – Vol. 22. – P. 56–64.

368